Jacquelyn W. Chou, MPP, MPL

Articles by Jacquelyn W. Chou, MPP, MPL

Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C

ByJacquelyn W. Chou, MPP, MPL,Marlon Graf, PhD,Oliver Díaz Espinosa, PhD,Iris Brewer, MS,Zachary Heim, BS,James Baumgardner, PhD

December 5th 2023

This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis.

Understanding and Improving Value Frameworks With Real-World Patient Outcomes

ByAnupam B. Jena, MD, PhD,Jacquelyn W. Chou, MPP, MPL,Lara Yoon, MPH,Wade M. Aubry, MD,Jan Berger, MD, MJ,Wayne Burton, MD,A. Mark Fendrick, MD,Donna M. Fick, RN, PhD,David Franklin, BA,Rebecca Killion, MA,Darius N. Lakdawalla, PhD,Peter J. Neumann, ScD,Kavita Patel, MD, MSHS,John Yee, MD, MPH,Brian Sakurada, PharmD,Kristina Yu-Isenberg, PhD, MPH, RPh

November 13th 2018

New value frameworks should incorporate real-world evidence that reflects patient treatment behavior, adherence to medication, and equity concerns arising from disparities in care.

Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events

ByAnupam B. Jena, MD, PhD,Daniel M. Blumenthal, MD, MBA,Warren Stevens, PhD,Jacquelyn W. Chou, MPP, MPL,Thanh G.N. Ton, PhD,Dana P. Goldman, PhD

June 15th 2016

Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.